PortfoliosLab logoPortfoliosLab logo

Highlights

Market Cap
$6.81B
Enterprise Value
$5.98B
EPS (TTM)
CN¥3.59
PE Ratio
15.87
PEG Ratio
0.34
Total Revenue (TTM)
CN¥58.25B
Gross Profit (TTM)
CN¥13.93B
EBITDA (TTM)
CN¥3.24B
Year Range
$8.26 - $19.45
ROA (TTM)
12.63%
ROE (TTM)
16.33%

Share Price Chart


Loading charts...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

ALBBY Performance Chart

Alibaba Health Information Technology Limited (ALBBY) is down 36.0% since the beginning of the year. At $8 per share, ALBBY is trading 56.7% below its 52-week high of $19. Investors who bought $1,000 worth of ALBBY shares 5 years ago would now be looking at an investment worth $192.


Loading charts...

S&P 500 Index

Returns By Period

Alibaba Health Information Technology Limited (ALBBY) has returned -35.96% so far this year and -29.88% over the past 12 months.


Alibaba Health Information Technology Limited

1D
-5.24%
1M
-10.95%
YTD
-35.96%
6M
-37.87%
1Y
-29.88%
3Y*
-11.57%
5Y*
-28.13%
10Y*

Benchmark (S&P 500 Index)

1D
-0.37%
1M
-0.01%
YTD
9.16%
6M
8.64%
1Y
25.22%
3Y*
19.78%
5Y*
11.99%
10Y*
13.88%
*Multi-year figures are annualized to reflect compound growth (CAGR)

ALBBY Monthly Returns History

Based on dividend-adjusted daily data since May 7, 2020, ALBBY's average daily return is -0.02%, while the average monthly return is -0.46%.

Historically, 41% of months were positive and 59% were negative. The best month was Nov 2022 with a return of +93.0%, while the worst month was Mar 2026 at -34.6%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 8 months.

On a daily basis, ALBBY closed higher 17% of trading days. The best single day was Dec 8, 2022 with a return of +32.0%, while the worst single day was Mar 26, 2026 at -35.2%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202630.29%-10.28%-34.57%19.90%-22.57%-9.81%-35.96%
20259.06%34.25%-6.54%2.10%-16.52%20.23%-0.57%5.77%51.27%-18.24%-6.78%-11.32%50.77%
2024-25.93%8.88%3.33%-23.44%26.80%-1.33%-3.44%-9.65%59.57%-14.17%-10.49%-5.48%-19.31%
20237.92%-24.91%1.29%0.00%-12.44%-5.28%17.21%-24.11%16.12%-6.32%4.21%-10.96%-38.88%
2022-8.52%-6.15%-6.68%-24.40%5.76%29.32%-4.45%-12.29%-19.50%-8.76%93.01%8.47%6.77%
20213.96%10.34%-17.14%5.88%-19.07%-7.24%-32.08%7.35%-19.90%-5.57%-26.51%-11.40%-72.88%

Benchmark Metrics

Alibaba Health Information Technology Limited has an annualized alpha of -11.38%, beta of 0.49, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since May 07, 2020.

  • This stock participated in 184.18% of S&P 500 Index downside but only 25.35% of its upside - more exposed to losses than it benefited from rallies.
  • Beta of 0.49 may look defensive, but with R2 of 0.01 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
  • R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
-11.38%
Beta
0.49
0.01
Upside Capture
25.35%
Downside Capture
184.18%

Return for Risk

Risk / Return Rank

ALBBY ranks 27 for risk / return — below 27% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.


ALBBY Risk / Return Rank: 2727
Overall Rank
ALBBY Sharpe Ratio Rank: 2727
Sharpe Ratio Rank
ALBBY Sortino Ratio Rank: 3232
Sortino Ratio Rank
ALBBY Omega Ratio Rank: 3333
Omega Ratio Rank
ALBBY Calmar Ratio Rank: 2424
Calmar Ratio Rank
ALBBY Martin Ratio Rank: 1818
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for Alibaba Health Information Technology Limited (ALBBY) and compare them to S&P 500 Index.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


ALBBYBenchmarkDifference
Sharpe ratioReturn per unit of total volatility

-2.38

Sortino ratioReturn per unit of downside risk

-2.72

Omega ratioGain probability vs. loss probability

1.01

1.37

-0.36

Calmar ratioReturn relative to maximum drawdown

-0.52

2.78

-3.31

Martin ratioReturn relative to average drawdown

-1.09

12.44

-13.53

Dividends

Dividend History


Alibaba Health Information Technology Limited doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading charts...

Worst Drawdowns

The table below displays the maximum drawdowns of the Alibaba Health Information Technology Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Alibaba Health Information Technology Limited was 91.29%, occurring on Apr 15, 2024. The portfolio has not yet recovered.

The current Alibaba Health Information Technology Limited drawdown is 89.35%.


Related event

Drawdown

Fall

Recovery

Underwater

2024 bear market2024
-91.29%Apr 2024
3y 1mo
5y 4moFeb 2021 - now
2020 bear market2020
-24.33%Sep 2020
8d3mo 1d
3mo 9dAug 2020 - Dec 2020
2021 correction2021
-12.55%Jan 2021
7d19d
26dJan 2021 - Feb 2021
2021 pullback2021
-8.39%Jan 2021
14d7d
21dDec 2020 - Jan 2021
2020 pullback2020
-2.79%Jul 2020
0s3d
3dJul 2020 - Jul 2020

Drawdown Indicators


ALBBYBenchmarkDifference

Max Drawdown

Largest peak-to-trough decline

-91.29%

-56.78%

-34.51%

Max Drawdown (1Y)

Largest decline over 1 year

-57.53%

-9.10%

-48.43%

Max Drawdown (3Y)

Largest decline over 3 years

-57.53%

-18.90%

-38.63%

Max Drawdown (5Y)

Largest decline over 5 years

-85.08%

-25.43%

-59.65%

Max Drawdown (10Y)

Largest decline over 10 years

-33.92%

Current Drawdown

Current decline from peak

-89.35%

-1.80%

-87.55%

Average Drawdown

Average peak-to-trough decline

-71.44%

-10.71%

-60.73%

Ulcer Index

Depth and duration of drawdowns from previous peaks

27.43%

2.03%

+25.40%

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading charts...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Alibaba Health Information Technology Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Alibaba Health Information Technology Limited is priced in the market compared to other companies in the Pharmaceutical Retailers industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PE Ratio

The chart displays the Price-to-Earnings (P/E) ratio for ALBBY, comparing it with other companies in the Pharmaceutical Retailers industry. Currently, ALBBY has a P/E ratio of 15.9. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.

PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for ALBBY compared to other companies in the Pharmaceutical Retailers industry. ALBBY currently has a PEG ratio of 0.3. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for ALBBY relative to other companies in the Pharmaceutical Retailers industry. Currently, ALBBY has a P/S ratio of 0.8. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for ALBBY in comparison with other companies in the Pharmaceutical Retailers industry. Currently, ALBBY has a P/B value of 2.6. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
Portfolio Analyzer

Build a portfolio with ALBBY

Add Alibaba Health Information Technology Limited to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Analyzer with ALBBY